
Antibodies are an essential part of our immune system, and over the years, scientists have developed a range of antibody-based drugs that are used to treat various diseases. In recent years, many antibody drugs have received approval from the US Food and Drug Administration (FDA) for their safety and effectiveness. Here are the top 10 antibody drugs approved by the FDA:
Humira (adalimumab): This antibody drug is used to treat a range of autoimmune diseases, including rheumatoid arthritis and psoriasis.
Rituxan (rituximab): This antibody drug is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.
Avastin (bevacizumab): This antibody drug is used to treat certain types of cancer, including colon, lung, and brain cancer.
Herceptin (trastuzumab): This antibody drug is used to treat HER2-positive breast cancer.
Remicade (infliximab): This antibody drug is used to treat autoimmune diseases, including Crohn's disease and rheumatoid arthritis.
Keytruda (pembrolizumab): This antibody drug is used to treat various types of cancer, including melanoma, lung cancer, and head and neck cancer.
Opdivo (nivolumab): This antibody drug is used to treat various types of cancer, including melanoma, lung cancer, and kidney cancer.
Erbitux (cetuximab): This antibody drug is used to treat colon cancer and head and neck cancer.
Prolia (denosumab): This antibody drug is used to treat osteoporosis.
Xolair (omalizumab): This antibody drug is used to treat asthma and allergic rhinitis.
At Biointron, we offer high-quality recombinant antibody production services that can help researchers and biotech companies develop antibody-based drugs for various diseases. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects.
In this article, we explore the major trends shaping the future of targeted canc……
Site-specific conjugation limits payload attachment to defined positions on the ……
Affinity maturation can improve binding to the intended target, but it can also ……
ADC development is no longer limited to the antibody-linker-toxin model. The fie……
Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.
Biointron uses cookies and similar technologies to ensure proper website functionality, understand how visitors use our website, and improve our content and services. Necessary cookies are enabled by default.
By clicking “Accept All”, you agree to the use of all cookies, including analytics and optional cookies that help us understand website usage and improve user experience. By clicking “Reject Non-Essential”, only necessary cookies will be used.
You may manage or change your cookie preferences at any time by clicking “Cookie Settings” at the bottom of the website.
For more information about how we use cookies and process personal data, please review our Privacy Policy.



